Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485556 | 0.84 | CNR2 (0.52) | ASIC3KDM4EMEN1NPC1MAPT | |
| SCHEMBL3484821 | 0.81 | CACNA1B (0.53) | ASIC3CNR1CNR2CACNA1B | |
| SCHEMBL31276039 | 0.81 | CYP26A1 (0.65) | CYP26A1CYP26B1KDM4EMEN1NPC1 | |
| SCHEMBL8598425 | 0.77 | ASIC3 (0.56) | ASIC3KDM4EMEN1NPC1MAPT | |
| SCHEMBL3485248 | 0.76 | CNR2 (0.44) | ASIC3CYP26A1CYP26B1KDM4ERAB9A | |
| SCHEMBL3485857 | 0.74 | PPARG (0.50) | CYP26A1CYP26B1KDM4EMEN1NPC1 | |
| SCHEMBL3485770 | 0.72 | KCNQ2 (0.42) | ASIC3KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL7912377 | 0.71 | NPC1 (0.62) | ASIC3KDM4EMEN1NPC1MAPT | |
| SCHEMBL3485725 | 0.71 | PTGDR2 (0.43) | CYP26A1CYP26B1KDM4ENPC1RAB9A | |
| SCHEMBL34460067 | 0.71 | CYP26B1 (0.74) | ASIC3CYP26A1CYP26B1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| EP-2150112-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008133867-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008133867-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | ASIC3 135/4885CYP26A1 3672/4885CYP26B1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.